VistaGen Therapeutics Earnings, Revenue miss In Q2

Investing.com - VistaGen Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
VistaGen Therapeutics announced earnings per share of $-0.080 on revenue of $-892.5K. Analysts polled by Investing.com anticipated EPS of $-0.070 on revenue of $340.03K.
VistaGen Therapeutics shares are down 53.92% from the beginning of the year and are trading at $0.130 , down-from-52-week-high.
VistaGen Therapeutics follows other major Healthcare sector earnings this month
VistaGen Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or